May the force be with you, too September 01, 2017By Peter J. McDonnell MDTomasso, a vitreoretinal surgeon, recently shared a blog by someone who calls him/herself “Neuroskeptic”.Neuroskeptic penned a spoof “scientific” article about midichlorians, which are the little organisms inside cells that give Jedi Knights (the good guys in the “Star Wars” movies) their powers (and unfortunately, confer those same powers to certain bad guys, like Darth Vader).
In this issue
Taking on surgery in HSV patients September 01, 2017By Laird HarrisonCataract and refractive surgeons should use prophylaxis to avoid reactivation of the herpes simplex virus (HSV) in patients with a history of infection with this virus, according to Elizabeth Yeu, MD. Expanding regimen with gel stent for surgical glaucoma managementHaving explored the various options available for micro-invasive glaucoma surgery (MIGS), I now use several devices with success. One MIGS device (XEN Gel Stent, Allergan) differs from the others in that it drains aqueous into the subconjunctival space and can be performed as a stand-alone procedure without cataract surgery or combined with cataract surgery. Flexible glaucoma procedure serves wide variety of patientsJuan Carlos Izquierdo, MD, decribes how CO2 laser-assisted sclerectomy surgery is a successful, less invasive, and more simple option for a wide range of glaucoma patients. Due to his overall success with the CLASS procedure, he no longer performs trabeculectomy. Progression of visual field loss not always easy to test, analyze September 01, 2017By Vanessa CaceresAssessing visual field progression in glaucoma may be more of an art than a science—and there is no one test to give reliable information that is needed about a patient, said Chris A. Johnson, PhD, DSc, FAAO, FARVO, professor, Department of Ophthalmology, and director, Visual Field Reading Center, University of Iowa, Iowa City. Neuroprotective strategy primed for progress September 01, 2017By Cheryl Guttman KraderAdvancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD. Fixed-combination glaucoma agent yields positive safety, efficacy data September 01, 2017By Vanessa CaceresA phase III trial for the fixed-combination netarsudil/latanoprost agent (Roclatan, Aerie Pharmaceuticals)reports positive results. The company plans to submit a NDA for the drug in early 2018. ABiC viable option for different stages severities of glaucoma September 01, 2017By Mark J. Gallardo MDWith its ability to restore the eye’s natural outflow pathway, ab-interno canaloplasty (ABiC) presents a viable option for the treatment of different stages and severities of glaucoma, according to Mark J. Gallardo, MD. IOP fluctuations important factor in setting patients’ target pressure September 01, 2017By Lynda ChartersWhen setting a target IOP for patients with glaucoma, consideration of IOP fluctuations and the degree to which they vary is important. What to do when the clinic has taken you hostageA dysfunctional clinic environment may mean the power lies with employees instead of the administration. Be aware of common complaints so the power of the practice can be taken back. Early surgical intervention with stent advantageous for certain glaucomasIt is well known that with most disease, the earlier it is detected, the better the outcome prognosis. Along with early detection comes the need for early treatment. Traditionally, options for glaucoma have been limited. Medications can be effective when used properly, though patients are notorious for compliance issues.